Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Basic Clin Pharmacol Toxicol ; 121(5): 414-422, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28544774

RESUMO

Hetrombopag olamine (hetrombopag) is a novel small-molecule, orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist that is being developed as the treatment for thrombocytopenia. Two randomized, placebo-controlled phase I studies were conducted in 72 healthy individuals to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of hetrombopag. Hetrombopag was orally administered with a single dose in five dose cohorts (5 mg, 10 mg, 20 mg, 30 mg or 40 mg) in the first study, and given once daily for 10 days in three dose cohorts (2.5 mg, 5.0 mg or 7.5 mg) in the second study, respectively. Hetrombopag was well tolerated, and the majority of adverse events associated with medicine were platelet elevations significantly above the normal range in healthy individuals. The single dose-escalation study revealed a Tmax of approximate 8 hr, and a t1/2 of 11.9 hr to 40.1 hr in a dose-prolonged manner. A dose-proportional increase in maximum concentration (Cmax ) of hetrombopag was observed, with area under the curve (AUC) increasing in a greater than dose-proportional manner. The plasma concentration of hetrombopag reached the steady-state after 7 days. The steady-state AUC0-24 hr and Cmax were dose-proportionally elevated from the 5.0 mg to 7.5 mg dose level. The potent pharmacological effect of the hetrombopag-induced platelet elevation was observed in a time- and dose-dependent manner. Furthermore, the thrombopoietic response was significantly (p < 0.0001) correlated to the plasma exposure level of hetrombopag in single and multiple administration studies. Taken together, results of this study support further clinical development of hetrombopag in patients with thrombocytopenia.


Assuntos
Hidrazonas/administração & dosagem , Pirazolonas/administração & dosagem , Receptores de Trombopoetina/agonistas , Administração Oral , Área Sob a Curva , Plaquetas/metabolismo , Relação Dose-Resposta a Droga , Método Duplo-Cego , Meia-Vida , Humanos , Hidrazonas/farmacocinética , Hidrazonas/farmacologia , Masculino , Pirazolonas/farmacocinética , Pirazolonas/farmacologia , Fatores de Tempo
2.
Bone ; 40(5): 1231-7, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17347064

RESUMO

Cathepsin K is a cysteine proteinase that is highly expressed by osteoclasts and is being pursued as a potential drug target for the treatment of osteoporosis. We have reported that microcomputed tomography (micro-CT) analysis of bone microarchitecture may serve as a valuable tool for evaluating both antiresorptive and anabolic agents in ovariectomized (OVX) mice. The purpose of this study was to evaluate the effect of SB-553484, a novel cathepsin K inhibitor (human Ki,app=0.14 nM, mouse Ki,app=26 nM), on the OVX mice by micro-CT bone morphometric analysis. Seven weeks female BALB/c mice were OVX or sham-operated. OVX animals were treated with SB-553484 (30 mg/kg, sc) or Rolipram (10 mg/kg, po), a phosphodiesterase 4 inhibitor used as a positive bone anabolic agent, twice a day for 2 weeks. Both SB-553484 and Rolipram significantly prevented the decrease of trabecular bone volume as well as the deterioration of trabecular architecture in OVX mice. Interestingly, SB-553484 demonstrated a more pronounced effect in improvement of trabecular separation, number and connectivity, and a weaker effect in improvement of trabecular thickness compared to that of Rolipram. These differences indicate that SB-553484 mainly acted as an antiresorptive agent in OVX-induced loss of trabecular bone. On the other hand, SB-553484 significantly increased cortical bone volume and cortical thickness as well as Rolipram in OVX mice indicating an unexpected stimulatory effect of SB-553484 on cortical bone formation. These data suggest that targeting cathepsin K may prove therapeutically beneficial in the treatment of diseases with accelerated bone loss such as postmenopausal osteoporosis not only by inhibiting bone resorption but also by potentially stimulating cortical bone formation.


Assuntos
Reabsorção Óssea/tratamento farmacológico , Catepsinas/antagonistas & inibidores , Osteogênese/efeitos dos fármacos , Ovariectomia , Inibidores de Proteases/farmacologia , Piridinas/farmacologia , Animais , Densidade Óssea/efeitos dos fármacos , Reabsorção Óssea/enzimologia , Catepsina K , Catepsinas/metabolismo , Células Cultivadas , Feminino , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Estrutura Molecular , Osteoclastos/efeitos dos fármacos , Osteoclastos/enzimologia , Inibidores de Proteases/química , Inibidores de Proteases/uso terapêutico , Piridinas/química , Piridinas/uso terapêutico , Tomografia Computadorizada por Raios X
3.
Invest Radiol ; 41(9): 704-12, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16896306

RESUMO

OBJECTIVES: The purposes of this study were to develop an osteoporosis model in a short period of 2 weeks after ovariectomy in mice and to investigate whether analysis of microcomputed tomography (muCT) 3-dimensional bone parameters could provide useful information on the mechanism of action of antiosteoporotic agents. MATERIALS AND METHODS: Mice were ovariectomized (OVX) or sham-operated, and the OVX mice were treated daily with 17beta-estradiol (E2), parathyroid hormone (PTH[1-34]), raloxifene, rolipram, or vehicle for 2 weeks. On day 14 post-OVX, the left femur bones were removed and then the distal metaphyseal bone was analyzed by both muCT and histomorphometry. RESULTS: The trabecular bone volume, thickness, number, and connectivity significantly decreased and the number of osteoclasts increased in OVX mice. Treatment of OVX animals with each of the 4 antiosteoporotic agents significantly increased the bone volume and improved the bone architecture. However, the improvement of trabecular thickness in the rolipram-treated group and that of cortical thickness in the PTH(1-34)-treated group were the most marked, whereas the improvement of connectivity in the rolipram-treated group was the least among the drug-treated groups. These different improving effects of agents on the bone parameters reflect the differential effects of these agents on bone formation and bone resorption. CONCLUSIONS: This study demonstrated the feasibility of evaluating the effect of the antiosteoporotic agents within 2 weeks after ovariectomy in mice. The muCT analysis may serve as a valuable tool, specifically in a high-throughput pharmacological screening test, offering useful information regarding the effects of test compounds on both bone resorption and formation.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Modelos Animais de Doenças , Imageamento Tridimensional , Osteoporose/diagnóstico , Osteoporose/prevenção & controle , Tomografia Computadorizada por Raios X , Animais , Reabsorção Óssea/diagnóstico , Reabsorção Óssea/tratamento farmacológico , Diagnóstico Precoce , Estradiol/uso terapêutico , Feminino , Fêmur/diagnóstico por imagem , Fêmur/efeitos dos fármacos , Fêmur/patologia , Camundongos , Osteogênese/efeitos dos fármacos , Ovariectomia , Hormônio Paratireóideo/uso terapêutico , Fragmentos de Peptídeos/uso terapêutico , Cloridrato de Raloxifeno/uso terapêutico , Rolipram/uso terapêutico
4.
J Appl Physiol (1985) ; 92(2): 763-70, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11796690

RESUMO

The aim of this study was to elucidate the role of thromboxane A(2) (TxA(2)) on asthma-related cough in guinea pigs. Animals were immunosensitized and repeatedly challenged with ovalbumin as an antigen. Coughs were induced by the inhalation of 10(-5) M capsaicin solution for 10 min. Thromboxane synthetase (TxS) inhibitor OKY-046 and thromboxane-receptor antagonist AA-2414 significantly inhibited cough responses in repeatedly challenged animals. Inhalation of TxA(2) mimic STA-2- potentiated cough responses in normal and immunosensitized animals but not in repeatedly challenged ones. Moreover, STA-2-potentiated coughs were inhibited by administration of neurokinin-receptor antagonist FK-224. In repeatedly challenged animals, concentration of TxB(2) in airway lavage fluid, expression of TxS mRNA in tracheal epithelia, and the immunostaining intensity against TxS in mucous cells of the epithelium significantly increased compared with normal and sensitized animals. These results suggest that TxA(2) derived from mucous cells potentiated cough responses to capsaicin in allergic airway inflammation.


Assuntos
Asma/complicações , Tosse/etiologia , Tosse/fisiopatologia , Mucosa Respiratória/fisiopatologia , Tromboxano A2/análogos & derivados , Tromboxano A2/fisiologia , Animais , Sequência de Bases , Líquido da Lavagem Broncoalveolar/química , DNA Complementar/genética , Feminino , Cobaias , Imuno-Histoquímica , Pulmão/enzimologia , RNA Mensageiro/metabolismo , Mucosa Respiratória/patologia , Tromboxano A2/análise , Tromboxano A2/farmacologia , Tromboxano-A Sintase/genética , Tromboxano-A Sintase/metabolismo , Traqueia/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...